Trials / Unknown
UnknownNCT05503953
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 306 (estimated)
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGSAVI | Uptitation |
| DRUG | AGLS | Uptitration |
Timeline
- Start date
- 2022-09-05
- Primary completion
- 2024-02-29
- Completion
- 2024-07-31
- First posted
- 2022-08-17
- Last updated
- 2022-08-18
Source: ClinicalTrials.gov record NCT05503953. Inclusion in this directory is not an endorsement.